| 1 | Ca-A Cancer Journal for Clinicians | 649.8 | 99th | Q1 | SCIE | – | No |
| 2 | Journal of Hematology and Oncology | 70.1 | 99th | Q1 | SCIE | – | Yes |
| 3 | Annals of Oncology | 69.6 | 98th | Q1 | SCIE | – | No |
| 4 | Journal of the National Cancer Center | 31.2 | 97th | Q1 | ESCI | – | Yes |
| 5 | The Lancet Haematology | 29.4 | 97th | Q1 | SCIE | – | No |
| 6 | Blood | 22.8 | 96th | Q1 | SCIE | – | No |
| 7 | Experimental Hematology and Oncology | 19.6 | 95th | Q1 | SCIE | – | Yes |
| 8 | Leukemia | 19.2 | 95th | Q1 | SCIE | – | No |
| 9 | Blood Cancer Journal | 16.2 | 94th | Q1 | SCIE | – | Yes |
| 10 | American Journal of Hematology | 14.9 | 93th | Q1 | SCIE | – | No |
| 11 | Blood Cancer Discovery | 13.9 | 93th | Q1 | ESCI | – | No |
| 12 | Blood Reviews | 12.7 | 92th | Q1 | SCIE | – | No |
| 13 | Blood Advances | 11.8 | 91th | Q1 | SCIE | – | Yes |
| 14 | Thrombosis and Haemostasis | 11 | 91th | Q1 | SCIE | – | No |
| 15 | Haematologica | 9.7 | 90th | Q1 | SCIE | – | Yes |
| 16 | Critical Reviews in Oncology/Hematology | 9.5 | 89th | Q1 | SCIE | – | No |
| 17 | Radiotherapy and Oncology | 9.1 | 89th | Q1 | SCIE | – | No |
| 18 | Journal of Thrombosis and Haemostasis | 8.8 | 88th | Q1 | SCIE | – | No |
| 19 | Seminars in Thrombosis and Hemostasis | 8.8 | 87th | Q1 | SCIE | – | No |
| 20 | Transplantation and Cellular Therapy | 8.1 | 87th | Q1 | SCIE | – | No |
| 21 | Journal of Clinical Laboratory Analysis | 8.1 | 86th | Q1 | SCIE | – | Yes |
| 22 | Bone Marrow Transplantation | 7.6 | 85th | Q1 | SCIE | – | No |
| 23 | Seminars in Hematology | 7.5 | 85th | Q1 | SCIE | – | No |
| 24 | Cytokine | 7.2 | 84th | Q1 | SCIE | – | No |
| 25 | HemaSphere | 6.9 | 83th | Q1 | SCIE | – | Yes |
| 26 | British Journal of Haematology | 6.6 | 83th | Q1 | SCIE | – | No |
| 27 | Platelets | 6.6 | 82th | Q1 | SCIE | – | Yes |
| 28 | Current Hematologic Malignancy Reports | 6.6 | 81th | Q1 | SCIE | – | No |
| 29 | Medical Oncology | 5.9 | 81th | Q1 | SCIE | – | No |
| 30 | Thrombosis Research | 5.8 | 80th | Q1 | SCIE | – | No |
| 31 | Current Opinion in HIV and AIDS | 5.8 | 79th | Q1 | SCIE | – | No |
| 32 | Hematology/Oncology Clinics of North America | 5.7 | 79th | Q1 | SCIE | – | No |
| 33 | Current Research in Translational Medicine | 5.5 | 78th | Q1 | SCIE | – | No |
| 34 | Current Opinion in Hematology | 5.4 | 77th | Q1 | SCIE | – | No |
| 35 | Transfusion Medicine Reviews | 5.3 | 77th | Q1 | SCIE | – | No |
| 36 | Therapeutic Advances in Hematology | 5.3 | 76th | Q1 | SCIE | – | Yes |
| 37 | Hematological Oncology | 5.2 | 75th | Q1 | SCIE | – | No |
| 38 | Vascular Health and Risk Management | 5.2 | 75th | Q1 | ESCI | – | Yes |
| 39 | Hematology (United States) | 5.1 | 74th | Q2 | SCIE | – | No |
| 40 | Journal of Thrombosis and Thrombolysis | 4.9 | 73th | Q2 | SCIE | – | No |
| 41 | Seminars in Oncology | 4.9 | 73th | Q2 | SCIE | – | No |
| 42 | Blood Research | 4.9 | 72th | Q2 | ESCI | – | Yes |
| 43 | Blood Transfusion | 4.8 | 71th | Q2 | SCIE | – | No |
| 44 | International Journal of Clinical Oncology | 4.8 | 71th | Q2 | SCIE | – | No |
| 45 | Research and Practice in Thrombosis and Haemostasis | 4.7 | 70th | Q2 | SCIE | – | Yes |
| 46 | Immunobiology | 4.7 | 69th | Q2 | SCIE | – | Yes |
| 47 | Blood Purification | 4.6 | 69th | Q2 | SCIE | – | No |
| 48 | Transfusion Medicine and Hemotherapy | 4.6 | 68th | Q2 | SCIE | – | Yes |
| 49 | European Journal of Haematology | 4.5 | 67th | Q2 | SCIE | – | No |
| 50 | Haemophilia | 4.4 | 67th | Q2 | SCIE | – | No |
| 51 | Journal of Blood Medicine | 4.4 | 66th | Q2 | ESCI | – | Yes |
| 52 | Cancer Control | 4.3 | 65th | Q2 | SCIE | – | Yes |
| 53 | Hematology/ Oncology and Stem Cell Therapy | 4.2 | 65th | Q2 | – | – | Yes |
| 54 | Blood Science | 4.2 | 64th | Q2 | ESCI | – | Yes |
| 55 | Clinical Hemorheology and Microcirculation | 4.1 | 63th | Q2 | SCIE | – | No |
| 56 | Expert Review of Hematology | 4.1 | 63th | Q2 | SCIE | – | No |
| 57 | Journal of Clinical Apheresis | 4.1 | 62th | Q2 | SCIE | – | No |
| 58 | Leukemia Research | 4.1 | 61th | Q2 | SCIE | – | No |
| 59 | Stem Cells and Development | 4 | 61th | Q2 | SCIE | – | No |
| 60 | Experimental Hematology | 4 | 60th | Q2 | SCIE | – | No |
| 61 | Acta Oncologica | 3.9 | 59th | Q2 | SCIE | – | Yes |
| 62 | Pediatric Blood and Cancer | 3.9 | 59th | Q2 | SCIE | – | No |
| 63 | Leukemia and Lymphoma | 3.9 | 58th | Q2 | SCIE | – | No |
| 64 | Clinical and Applied Thrombosis/Hemostasis | 3.8 | 57th | Q2 | SCIE | – | Yes |
| 65 | Hamostaseologie | 3.8 | 57th | Q2 | SCIE | – | No |
| 66 | Thrombosis Journal | 3.8 | 56th | Q2 | SCIE | – | Yes |
| 67 | Blood Cells, Molecules, and Diseases | 3.7 | 55th | Q2 | SCIE | – | No |
| 68 | International Journal of Laboratory Hematology | 3.6 | 55th | Q2 | SCIE | – | No |
| 69 | Kidney and Dialysis | 3.5 | 54th | Q2 | ESCI | – | Yes |
| 70 | Clinical Hematology International | 3.4 | 53th | Q2 | – | – | Yes |
| 71 | International Journal of Hematology | 3.4 | 53th | Q2 | SCIE | – | No |
| 72 | Anemia | 3.3 | 52th | Q2 | ESCI | – | Yes |
| 73 | Annals of Hematology | 3.3 | 51th | Q2 | SCIE | – | Yes |
| 74 | Hematology (United Kingdom) | 3.2 | 51th | Q2 | SCIE | – | Yes |
| 75 | Mediterranean Journal of Hematology and Infectious Diseases | 3.2 | 50th | Q2 | SCIE | – | Yes |
| 76 | Transfusion | 3.2 | 50th | Q2 | SCIE | – | No |
| 77 | Vox Sanguinis | 3.2 | 49th | Q3 | SCIE | – | No |
| 78 | Therapeutic Apheresis and Dialysis | 3 | 48th | Q3 | SCIE | – | No |
| 79 | Current Medicinal Chemistry: Cardiovascular and Hematological Agents | 2.9 | 48th | Q3 | – | – | No |
| 80 | Acta Haematologica | 2.9 | 47th | Q3 | SCIE | – | No |
| 81 | Turkish Journal of Hematology | 2.7 | 46th | Q3 | SCIE | – | Yes |
| 82 | Annals of Blood | 2.6 | 46th | Q3 | ESCI | – | No |
| 83 | Clinical Lymphoma, Myeloma and Leukemia | 2.6 | 45th | Q3 | SCIE | – | No |
| 84 | Oncology Research and Treatment | 2.4 | 44th | Q3 | SCIE | – | No |
| 85 | Transfusion Medicine | 2.3 | 44th | Q3 | SCIE | – | No |
| 86 | Pediatric Hematology and Oncology | 2.3 | 43th | Q3 | SCIE | – | No |
| 87 | Blood Coagulation and Fibrinolysis | 2.3 | 42th | Q3 | SCIE | – | No |
| 88 | Hematology Reports | 2.3 | 42th | Q3 | ESCI | – | Yes |
| 89 | Hematology, Transfusion and Cell Therapy | 2.2 | 41th | Q3 | ESCI | – | Yes |
| 90 | EJC Paediatric Oncology | 2.2 | 40th | Q3 | ESCI | – | Yes |
| 91 | Hemodialysis International | 2.2 | 40th | Q3 | SCIE | – | No |
| 92 | Transfusion Clinique et Biologique | 2.2 | 39th | Q3 | SCIE | – | No |
| 93 | Journal of Clinical and Experimental Hematopathology | 2.2 | 38th | Q3 | ESCI | – | Yes |
| 94 | Thrombosis Update | 2.2 | 38th | Q3 | – | – | Yes |
| 95 | Transfusion and Apheresis Science | 2.1 | 37th | Q3 | SCIE | – | No |
| 96 | Flebologiya | 2 | 36th | Q3 | – | – | No |
| 97 | Hemato | 1.9 | 36th | Q3 | ESCI | – | Yes |
| 98 | Journal of Pediatric Hematology/Oncology | 1.8 | 35th | Q3 | SCIE | – | No |
| 99 | Cardiovascular and Hematological Disorders - Drug Targets | 1.8 | 34th | Q3 | – | – | No |
| 100 | Hemoglobin | 1.8 | 34th | Q3 | SCIE | – | No |